ATF1 and non-small cell lung carcinoma: Subsequently, MSKs phosphorylate and activate Activator Protein component (ATF1) at Ser63, initiating gene transcription.[14] These contributed to the pathogenesis of NSCLC.[15] Understanding and addressing the underlying mechanisms is crucial for developing strategies to overcome resistance and improving NSCLC treatment outcomes.[12, 15]